Eylea (Aflibercept, BAY86-5321)
20275
Phase 3 small_molecule completed
Quick answer
Eylea (Aflibercept, BAY86-5321) for Retinopathy of Prematurity (ROP) is a Phase 3 program (small_molecule) at Regeneron UK Limited with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Retinopathy of Prematurity (ROP)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed